Remedee Labs offers a non-invasive neuromodulation device that utilizes millimeter-wave technology to stimulate peripheral nerves, promoting the release of endorphins for pain relief. This solution addresses the needs of the 12 million individuals in France suffering from chronic pain, many of whom do not receive adequate treatment from existing therapies.
Funding
$30.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with chronic conditions such as fibromyalgia and osteoarthritis often rely on medication or frequent clinical visits to manage pain, fatigue, sleep disturbances, and anxiety. These approaches can be invasive, have side effects, and may not provide consistent relief.
Solution
Remedee offers a medical-grade wearable bracelet that delivers millimeter‑wave neuromodulation to stimulate endogenous endorphin release, providing non‑pharmacological pain relief. The device is paired with the my Remedee mobile app and a personalized human monitoring service, creating a connected care program. Clinical trials in eight French pain centers have demonstrated statistically significant reductions in pain intensity and improvements in associated symptoms after 6–8 weeks of regular use (3–5 sessions per day). The solution is certified as a medical device, enabling patients to self‑administer therapy at home while clinicians can track progress remotely.
Target Audience
Primary users are individuals with chronic musculoskeletal pain—specifically those diagnosed with fibromyalgia or peripheral osteoarthritis—seeking a drug‑free, home‑based therapy, as well as clinicians who manage these conditions.
Features
- Millimeter‑wave neuromodulation bracelet that autonomously triggers endorphin secretion
- Integrated my Remedee app for session scheduling, symptom logging, and data visualization
- Personalized remote monitoring by healthcare professionals for adherence and outcome assessment
- Clinically validated in eight French pain‑treatment centers with real‑world data up to 18 months
- Targeted protocols for fibromyalgia (Fibro Rem™) and osteoarthritis (Novi Rem™)
- Subscription‑based cloud platform that stores encrypted usage data and generates progress reports